|

Nilotinib Hydrochloride Monohydrate Clinical Trials

1 actively recruiting trial across 1 location

Also known as: AMN 107, AMN-107, AMN107, Nilotinib Monohydrochloride Monohydrate, Tasigna

Pipeline

Phase 2: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Unresectable HER2-Negative Breast Carcinoma1
  • Recurrent Ovarian Carcinoma1
  • Metastatic HER2 Negative Breast Carcinoma1
  • Locally Advanced Malignant Solid Neoplasm1
  • Recurrent Malignant Female Reproductive System Neoplasm1

Birmingham, Alabama1 trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.